

Laurence Amar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9068530/publications.pdf>

Version: 2024-02-01

149
papers

14,276
citations

26630

56
h-index

20358

116
g-index

161
all docs

161
docs citations

161
times ranked

9901
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e85-e93.	1.8	19
2	Colocalization of Wnt/ β 2-Catenin and ACTH Signaling Pathways and Paracrine Regulation in Aldosterone-producing Adenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 419-434.	3.6	5
3	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. <i>Hypertension</i> , 2022, 79, 187-195.	2.7	13
4	Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 519-530.	3.1	16
5	How to Explore an Endocrine Cause of Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 420.	2.4	5
6	Hypertension With Negative Metaiodobenzylguanidine Scintigraphy. <i>Hypertension</i> , 2022, 79, 474-478.	2.7	1
7	Perioperative outcomes of pheochromocytoma/paraganglioma surgery preceded by Takotsubo-like cardiomyopathy. <i>Surgery</i> , 2022, 172, 913-918.	1.9	2
8	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3689-e3698.	3.6	4
9	The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex – a multicenter-study of 3566 Caucasian and Asian subjects. <i>European Journal of Endocrinology</i> , 2022, 187, 361-372.	3.7	9
10	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI) – clinical phenotypes and their predictors based on a cohort of 1000 patients. <i>Cardiovascular Research</i> , 2021, 117, 950-959.	3.8	33
11	Acute Stress Cardiomyopathy: Heart of pheochromocytoma. <i>Annales D'Endocrinologie</i> , 2021, 82, 201-205.	1.4	10
12	Screening of a Large Cohort of Asymptomatic <i>SDHx</i> Mutation Carriers in Routine Practice. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1301-e1315.	3.6	10
13	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2726-2737.	3.6	8
14	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444.	9.6	80
15	Male Sex Is Associated With Cervical Artery Dissection in Patients With Fibromuscular Dysplasia. <i>Journal of the American Heart Association</i> , 2021, 10, e018311.	3.7	7
16	Renal Outcome and New-Onset Renal and Extrarenal Dissections in Patients With Nontrauma Renal Artery Dissection Associated With Renal Infarction. <i>Hypertension</i> , 2021, 78, 51-61.	2.7	8
17	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4340-e4349.	3.6	18
18	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. <i>Nature Genetics</i> , 2021, 53, 1360-1372.	21.4	37

#	ARTICLE	IF	CITATIONS
19	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. <i>Hypertension</i> , 2021, 78, 898-911.	2.7	12
20	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1111-e1128.	3.6	19
21	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. <i>Nature Communications</i> , 2021, 12, 6031.	12.8	34
22	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2042-2052.	3.6	65
23	Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 898-907.	3.6	11
24	Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1510-1517.	6.4	22
25	Aldosterone-Related Myocardial Extracellular Matrix Expansion in Hypertension in Humans. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2149-2159.	5.3	23
26	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1919-1928.	0.5	151
27	Genetic, Cellular, and Molecular Heterogeneity in Adrenals With Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2020, 75, 1034-1044.	2.7	89
28	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	3.6	17
29	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1443-1456.	0.5	190
30	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1440.	7.1	57
31	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. <i>Theranostics</i> , 2019, 9, 4946-4958.	10.0	54
32	Retinoic acid receptor β as a novel contributor to adrenal cortex structure and function through interactions with Wnt and Vegfa signalling. <i>Scientific Reports</i> , 2019, 9, 14677.	3.3	10
33	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. <i>Hypertension</i> , 2019, 74, 800-808.	2.7	97
34	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. <i>Journal of Medical Genetics</i> , 2019, 56, 513-520.	3.2	60
35	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1109-1118.	3.6	82
36	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	3.6	103

#	ARTICLE	IF	CITATIONS
37	Pheochromocytoma/Paraganglioma: Management, Genetics, and Follow-up. , 2019, , 469-477.		0
38	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2019, 25, 760-770.	7.0	82
39	Usefulness of Magnetic Resonance Imaging in the Diagnosis of Juxtaglomerular Cell Tumors: A Report of 10 Cases and Review of the Literature. <i>American Journal of Kidney Diseases</i> , 2019, 73, 566-571.	1.9	13
40	SAT-012 Urinary Aldosterone Assay Using LC-MS/MS Could Improve Primary Aldosteronism Screening. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	1
41	Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration. <i>Journal of Hypertension</i> , 2018, 36, 1592-1601.	0.5	24
42	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier <i>SLC25A11</i> Gene Confer a Predisposition to Metastatic Paragangliomas. <i>Cancer Research</i> , 2018, 78, 1914-1922.	0.9	96
43	A gain-of-function mutation in the <i>CLCN2</i> chloride channel gene causes primary aldosteronism. <i>Nature Genetics</i> , 2018, 50, 355-361.	21.4	154
44	Macrolides for <i>KCNJ5</i> -mutated aldosterone-producing adenoma (MAPA): design of a study for personalized diagnosis of primary aldosteronism. <i>Blood Pressure</i> , 2018, 27, 200-205.	1.5	25
45	Sex differences in antihypertensive treatment in France among 17 856 patients in a tertiary hypertension unit. <i>Journal of Hypertension</i> , 2018, 36, 939-946.	0.5	14
46	Arterial stiffness evaluated by pulse wave velocity is not predictive of the improvement in hypertension after adrenal surgery for primary aldosteronism: A multicentre study from the French European Society of Hypertension Excellence Centres. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 564-572.	1.6	3
47	Cause of renal infarction. <i>Journal of Hypertension</i> , 2018, 36, 634-640.	0.5	31
48	MicroRNA-204 Is Necessary for Aldosterone-Stimulated T-Type Calcium Channel Expression in Cardiomyocytes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2941.	4.1	11
49	Resistant Hypertension. , 2018, , 398-408.		1
50	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. <i>Genetics in Medicine</i> , 2018, 20, 1652-1662.	2.4	45
51	Pheochromocytoma: When to search a germline defect?. <i>Presse Medicale</i> , 2018, 47, e109-e118.	1.9	10
52	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
53	Case of Primary Aldosteronism With Discordant Hormonal and Computed Tomographic Findings. <i>Hypertension</i> , 2017, 69, 529-535.	2.7	1
54	Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. <i>Hypertension</i> , 2017, 69, 985-991.	2.7	3

#	ARTICLE	IF	CITATIONS
55	Awareness of Individual Cardiovascular Risk Factors and Self-Perception of Cardiovascular Risk in Women. <i>American Journal of the Medical Sciences</i> , 2017, 354, 240-245.	1.1	6
56	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 689-699.	11.4	595
57	Risk assessment of maternally inherited <i>SDHD</i> paraganglioma and pheochromocytoma. <i>Journal of Medical Genetics</i> , 2017, 54, 125-133.	3.2	37
58	High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia. <i>Hypertension</i> , 2017, 70, 652-658.	2.7	115
59	Diagnostic criteria for adrenal venous sampling. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 218-224.	2.3	8
60	The <i>MITF</i> , p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4764-4768.	3.6	16
61	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3205.	3.6	44
62	European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a pheochromocytoma or a paraganglioma. <i>European Journal of Endocrinology</i> , 2016, 174, G1-G10.	3.7	352
63	Primary aldosteronism and pregnancy. <i>Annales D'Endocrinologie</i> , 2016, 77, 148-160.	1.4	43
64	MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R135-R145.	3.7	52
65	Adherence to Antihypertensive Treatment and the Blood Pressure—Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. <i>Circulation</i> , 2016, 134, 847-857.	1.6	144
66	Suppression of Aldosterone Secretion After Recumbent Saline Infusion Does Not Exclude Lateralized Primary Aldosteronism. <i>Hypertension</i> , 2016, 68, 989-994.	2.7	23
67	CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism. <i>EBioMedicine</i> , 2016, 13, 225-236.	6.1	119
68	[OP.3A.02] RETINOIC ACID RECEPTOR SIGNALING CONTRIBUTES TO ADRENAL CORTEX MORPHOLOGY AND FUNCTIONAL ZONATION. <i>Journal of Hypertension</i> , 2016, 34, e26.	0.5	0
69	[OP.2A.07] TRENDS IN PATIENTS ATTENDING A TERTIARY HYPERTENSION UNIT. <i>Journal of Hypertension</i> , 2016, 34, e17.	0.5	0
70	[OP.2B.08] ETIOLOGY OF RENAL INFARCTIONS. <i>Journal of Hypertension</i> , 2016, 34, e20-e21.	0.5	1
71	[OP.3A.06] LONG TERM FOLLOW-UP IN PATIENTS OPERATED ON A PHEOCHROMOCYTOMA OR A PARAGANGLIOMA. <i>Journal of Hypertension</i> , 2016, 34, e28.	0.5	0
72	[OP.LB01.12] CACNA1H MUTATIONS ARE ASSOCIATED WITH YOUNG ONSET AND FAMILIAL FORMS OF PRIMARY ALDOSTERONISM. <i>Journal of Hypertension</i> , 2016, 34, e39.	0.5	0

#	ARTICLE	IF	CITATIONS
73	[OP.7D.02] INCREASE IN PLASMA COPEPTIN CONCENTRATION IN PATIENTS WITH CONFIRMED RESISTANT ESSENTIAL HYPERTENSION. <i>Journal of Hypertension</i> , 2016, 34, e94.	0.5	0
74	SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. <i>Annales D'Endocrinologie</i> , 2016, 77, 179-186.	1.4	50
75	SFE/SFHTA/AFCE consensus on primary aldosteronism, part 3: Confirmatory testing. <i>Annales D'Endocrinologie</i> , 2016, 77, 202-207.	1.4	34
76	SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery. <i>Annales D'Endocrinologie</i> , 2016, 77, 220-225.	1.4	23
77	<i>In Vivo</i> Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. <i>Clinical Cancer Research</i> , 2016, 22, 1120-1129.	7.0	54
78	Artériopathie athéromateuse des artères rénales. , 2016, , 221-225.		0
79	CO-33: Different somatic mutations in multinodular adrenals with aldosterone-producing adenoma. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2015, 64, S16.	0.6	0
80	CO-14: Assessment of patients attending hypertension consultations at University Hospital Georges Pompidou in the last 15 years. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2015, 64, S8-S9.	0.6	0
81	P3-22: Renal infarction : etiology analysis in a 244 case series. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2015, 64, S30.	0.6	0
82	CO-34: Retinoic acid receptor signaling contributes to adrenal morphology and functional zonation. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2015, 64, S16.	0.6	0
83	LB01.11. <i>Journal of Hypertension</i> , 2015, 33, e47.	0.5	28
84	Influence of Diagnostic Criteria on the Interpretation of Adrenal Vein Sampling. <i>Hypertension</i> , 2015, 65, 849-854.	2.7	48
85	SDHD Immunohistochemistry: A New Tool to Validate SDHx Mutations in Pheochromocytoma/Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E287-E291.	3.6	45
86	Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 1957-1965.	13.7	453
87	Diagnosing pheochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. <i>Clinical Endocrinology</i> , 2015, 83, 298-302.	2.4	35
88	Functional histopathological markers of aldosterone producing adenoma and somatic KCNJ5 mutations. <i>Molecular and Cellular Endocrinology</i> , 2015, 408, 220-226.	3.2	23
89	Outcomes of Drug-Based and Surgical Treatments for Primary Aldosteronism. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 196-203.	1.4	19
90	PROGRESS IN PRIMARY ALDOSTERONISM: Mineralocorticoid antagonist treatment for aldosterone-producing adenoma. <i>European Journal of Endocrinology</i> , 2015, 172, R125-R129.	3.7	14

#	ARTICLE	IF	CITATIONS
91	Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma. Hypertension, 2015, 66, 1014-1022.	2.7	55
92	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
93	Mast Cell Hyperplasia Is Associated With Aldosterone Hypersecretion in a Subset of Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E550-E560.	3.6	32
94	Deciphering the Role of Vasopressin in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3297-3303.	3.6	8
95	Paraganglioma and pheochromocytoma: from genetics to personalized medicine. Nature Reviews Endocrinology, 2015, 11, 101-111.	9.6	396
96	Statut tensionnel, phénotype sérologique et potentiel métastatique chez les patients porteurs de phéochromocytome ou de paragangliome : données génétiques et physio-pathologiques récentes. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 313-319.	0.0	0
97	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
98	WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Human Molecular Genetics, 2014, 23, 889-905.	2.9	157
99	Peritoneal Implantation of Pheochromocytoma Following Tumor Capsule Rupture During Surgery. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2681-E2685.	3.6	33
100	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 2014, 135, 2711-2720.	5.1	155
101	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
102	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics, 2014, 23, 2440-2446.	2.9	316
103	KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Molecular and Cellular Endocrinology, 2013, 371, 221-227.	3.2	38
104	Aldosterone synthase inhibition in humans. Nephrology Dialysis Transplantation, 2013, 28, 36-43.	0.7	79
105	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	21.4	460
106	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell, 2013, 23, 739-752.	16.8	606
107	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4006-4012.	3.6	102
108	Imaging Work-Up for Screening of Paraganglioma and Pheochromocytoma in SDHx Mutation Carriers: A Multicenter Prospective Study from the PGL.EVA Investigators. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E162-E173.	3.6	130

#	ARTICLE	IF	CITATIONS
109	Cardiovascular Complications Associated With Primary Aldosteronism. <i>Hypertension</i> , 2013, 62, 331-336.	2.7	402
110	Can we use mineralocorticoid receptor blockade in diabetic patients with resistant hypertension? Yes we can! But it may be a double-edged sword. <i>Journal of Hypertension</i> , 2013, 31, 1948-1951.	0.5	0
111	Acute catecholamine cardiomyopathy in patients with pheochromocytoma or functional paraganglioma. <i>Heart</i> , 2013, 99, 1438-1444.	2.9	105
112	Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. <i>Journal of Hypertension</i> , 2013, 31, 624-629.	0.5	31
113	Primary adrenal angiosarcoma and functioning adrenocortical adenoma: an exceptional combined tumor. <i>European Journal of Endocrinology</i> , 2012, 166, 131-135.	3.7	19
114	Outcomes of Adrenalectomy in Patients with Unilateral Primary Aldosteronism: A Review. <i>Hormone and Metabolic Research</i> , 2012, 44, 221-227.	1.5	102
115	Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E954-E962.	3.6	87
116	<i>KCNJ5</i> Mutations in European Families With Nonglucocorticoid Remediable Familial Hyperaldosteronism. <i>Hypertension</i> , 2012, 59, 235-240.	2.7	176
117	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. <i>Human Molecular Genetics</i> , 2012, 21, 5397-5405.	2.9	126
118	Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma. <i>Hormone and Metabolic Research</i> , 2012, 44, 385-389.	1.5	66
119	<i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2012, 18, 2828-2837.	7.0	277
120	A Clinical Prediction Score to Diagnose Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3530-3537.	3.6	148
121	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1606-1614.	3.6	310
122	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. <i>Hypertension</i> , 2012, 59, 592-598.	2.7	246
123	Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma. <i>Endocrine Pathology</i> , 2012, 23, 34-42.	9.0	75
124	Ectopic Hormone-Secreting Pheochromocytoma: A Francophone Observational Study. <i>World Journal of Surgery</i> , 2012, 36, 1382-1388.	1.6	27
125	Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. <i>Human Molecular Genetics</i> , 2011, 20, 3974-3985.	2.9	266
126	Aldosterone-Producing Adenoma Formation in the Adrenal Cortex Involves Expression of Stem/Progenitor Cell Markers. <i>Endocrinology</i> , 2011, 152, 4753-4763.	2.8	85

#	ARTICLE	IF	CITATIONS
127	Inactivation of the <i>APC</i> Gene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers. <i>Clinical Cancer Research</i> , 2010, 16, 5133-5141.	7.0	97
128	Aldosterone Synthase Inhibition With LCI699. <i>Hypertension</i> , 2010, 56, 831-838.	2.7	161
129	Adrenal Cortex Remodeling and Functional Zona Glomerulosa Hyperplasia in Primary Aldosteronism. <i>Hypertension</i> , 2010, 56, 885-892.	2.7	128
130	Primary stenting for atherosclerotic renal artery stenosis. <i>Journal of Vascular Surgery</i> , 2010, 51, 1574-1580.e1.	1.1	17
131	Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. <i>Orphanet Journal of Rare Diseases</i> , 2010, 5, 9.	2.7	60
132	Pheochromocytomas and functional paragangliomas: Clinical management. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 933-941.	4.7	19
133	The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. <i>PLoS ONE</i> , 2009, 4, e7094.	2.5	203
134	Fasting Plasma Glucose and Serum Lipids in Patients With Primary Aldosteronism. <i>Hypertension</i> , 2009, 53, 605-610.	2.7	111
135	The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2817-2827.	3.6	353
136	An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. <i>Lancet Oncology</i> , The, 2009, 10, 764-771.	10.7	477
137	Does stenting for atherosclerotic renovascular disease improve blood pressure and kidney function better than medical treatment?. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 612-613.	0.4	0
138	RECENT ADVANCES IN THE GENETICS OF PHAEOCHROMOCYTOMA AND FUNCTIONAL PARAGANGLIOMA. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 376-379.	1.9	55
139	SELECTION OF PATIENTS FOR SURGERY FOR PRIMARY ALDOSTERONISM. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 522-525.	1.9	4
140	Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. <i>Journal of Hypertension</i> , 2008, 26, 1816-1823.	0.5	117
141	Apports de COMETE à la génétique du phéochromocytome. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2008, 192, 105-116.	0.0	1
142	Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3822-3828.	3.6	399
143	Changes in Urinary Total Metanephrine Excretion in Recurrent and Malignant Pheochromocytomas and Secreting Paragangliomas. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 383-391.	3.8	26
144	Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2110-2116.	3.6	324

#	ARTICLE	IF	CITATIONS
145	Genetic Testing in Pheochromocytoma or Functional Paraganglioma. <i>Journal of Clinical Oncology</i> , 2005, 23, 8812-8818.	1.6	612
146	Hereditary Paraganglioma/Pheochromocytoma and Inherited Succinate Dehydrogenase Deficiency. <i>Hormone Research in Paediatrics</i> , 2005, 63, 171-179.	1.8	57
147	Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 774-777.	0.7	109
148	Video-assisted thoracoscopic surgery as a first-line treatment for mediastinal parathyroid adenomas: strategic value of imaging. <i>European Journal of Endocrinology</i> , 2004, 150, 141-147.	3.7	26
149	Hereditary angio-oedema: effective treatment with the progestogen-only pill in a young woman. <i>British Journal of Dermatology</i> , 2004, 151, 713-714.	1.5	11